Lazard is acting as the exclusive financial advisor to Collegium. Hogan Lovells is serving as M&A legal counsel to Collegium. Goodwin Procter LLP is serving as...
You must be a Standard 1 Year member to access this content.
Goodwin advised Generate:Biomedicines on the fundraising. Generate:Biomedicines announced that it has raised $273 million in Series C financing. This financing round attracted many new investors including...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised PointClickCare Corp. on the deal. PointClickCare Corp. announced its acquisition of Patient Pattern. The combination of PointClickCare and Patient Pattern will further the companies’...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised PTC on the deal, Ropes & Gray represented ServiceMax, Latham & Watkins represented Centerview Partners. PTC (NASDAQ: PTC) signed its definitive agreement to acquire...
You must be a Standard 1 Year member to access this content.
Goodwin advised Generate Biomedicine on the deal. Generate Biomedicines announced its research collaboration agreement with Amgen (NASDAQ: AMGN) to discover and create protein therapeutics for five clinical...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Salsify on the deal. Salsify announced its acquisition of SKUvantage, Australia’s leading product content solutions provider. This acquisition will serve as a basis for...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Wellframe on the deal. Wellframe Inc. announced its definitive agreement to be acquired by HealthEdge Software. Wellframe strategically partners with health plans nationwide to...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Valo Health on the deal, while Latham & Watkins LLP represented Khosla Ventures Acquisition Co. Valo Health announced its definitive merger agreement with...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Valo Health on the deal. Valo Health announced the final closing of its Series B at $300 million, including a $110 million...
You must be a Standard 1 Year member to access this content.
